003020.SHE Hefei Lifeon Pharmaceutical Co Ltd
- Market cap
- CNY 3.38B
- P/E
- 20.6x
- P/B
- 1.84x
- ROE
- 9.6%
- Dividend yield
- 4.92%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003020.SHE undervalued?
Graham number003020.SHE trades 29.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hefei Lifeon Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hefei Lifeon Pharmaceutical Co Ltd yet.
Hefei Lifeon Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides i…
Full company profileHefei Lifeon Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hefei Lifeon Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.03B | 1.17B | 1.42B | 1.65B | 1.89B | 2.27B | 2.58B | 1.90B | 1.52B | 1.55B | 1.37B |
| Gross Profit | 188M | 258M | 426M | 516M | 633M | 904M | 960M | 969M | 1.04B | 1.00B | 909M |
| Operating Income | 75.1M | 90.0M | 108M | 119M | 157M | 192M | 240M | 255M | 178M | 166M | 194M |
| EBITDA | 94.2M | 105M | 122M | 137M | 173M | 224M | 267M | 295M | 249M | 275M | 193M |
| Net Income | 67.5M | 76.8M | 91.7M | 105M | 135M | 172M | 209M | 227M | 161M | 165M | 176M |
| EPS | 0.50 | 0.57 | 0.68 | 0.74 | 0.96 | 0.92 | 1.11 | 1.18 | 0.84 | 0.72 | 0.77 |
| Balance Sheet | |||||||||||
| Total Assets | 548M | 613M | 771M | 890M | 1.54B | 1.67B | 2.12B | 2.48B | 2.59B | 2.59B | 2.61B |
| Total Liabilities | 250M | 251M | 265M | 300M | 362M | 371M | 642M | 610M | 673M | 634M | 635M |
| Shareholders' Equity | 298M | 362M | 506M | 590M | 1.17B | 1.30B | 1.48B | 1.69B | 1.74B | 1.81B | 1.84B |
| Cash & Short-term Investments | 75.8M | 76.4M | 154M | 223M | 767M | 654M | 643M | 564M | 498M | 414M | 227M |
| Total Debt | 50.0M | 65.0M | 35.0M | 24.0M | 181M | 24.6M | 13.4M | 33.9M | 64.2M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 59.0M | 11.3M | 64.5M | 149M | 172M | 159M | 201M | 204M | 198M | 213M | - |
| Capital Expenditure | 12.7M | 11.5M | 29.2M | 43.9M | 56.2M | 187M | 246M | 198M | 154M | 118M | 126M |
| Free Cash Flow | 46.3M | -132K | 35.3M | 105M | 116M | -28.2M | -45.8M | 6.14M | 43.0M | 94.4M | 199M |
| Ratios | |||||||||||
| ROE | 22.6% | 21.2% | 18.1% | 17.8% | 11.5% | 13.2% | 14.1% | 13.4% | 9.2% | 9.1% | 9.6% |
| ROA | 12.3% | 12.5% | 11.9% | 11.8% | 8.8% | 10.3% | 9.9% | 9.1% | 6.2% | 6.4% | 6.7% |
| Net Profit Margin | 6.6% | 6.6% | 6.4% | 6.4% | 7.1% | 7.6% | 8.1% | 11.9% | 10.6% | 10.6% | 12.9% |
| Debt to Equity | 0.17x | 0.18x | 0.07x | 0.04x | 0.15x | 0.02x | 0.01x | 0.02x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hefei Lifeon Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.92%
- Forward dividend
- 0.47 CNY
- Payout ratio
- 100.6%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 166M | 0.73 | 100.6% |
| 2024 | CNY 80.9M | 0.42 | 50.4% |
| 2023 | CNY 61.3M | 0.32 | 27.0% |
| 2022 | CNY 64.8M | 0.34 | 31.0% |
| 2021 | CNY 46.3M | 0.25 | 26.9% |
| 2020 | CNY 27.8M | 0.20 | 20.6% |
| 2019 | CNY 20.8M | 0.15 | 19.8% |
| 2018 | 22.4M | 0.17 | 24.4% |
| 2017 | 16.3M | 0.12 | 21.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on May 29, 2026.
Who owns Hefei Lifeon Pharmaceutical Co Ltd
- Insiders 64.68%
- Institutions 1.17%
- Public & others 34.15%
- Shares outstanding 228M
- Free float 99.0M
Hefei Lifeon Pharmaceutical Co Ltd company profile
- Company name
- Hefei Lifeon Pharmaceutical Co Ltd
- Ticker
- 003020.SHE
- ISIN
- CNE100004BD9
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,465
- Fiscal year end
- December
- Address
- Cube Factory, Hefei, China, 230088
- Phone
- 86 551 6535 0370
- Website
- lifeonapi.com
About Hefei Lifeon Pharmaceutical Co Ltd
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides intermediate products, such as sodium paeonolsilate, methy2-(2,3-dichlorobenzylidine)-acetoacetate, 3-mercapto-1-propanol, mercaptosuccinic acid and DMPS monohydrate. In addition, it offers nifedipine controlled, doxazosin mesylate, felodipine, trimetazidine dihydrochloride prolonged release tablets; venlafaxine, methylphenidate, and oxycodone hydrochloride prolonged release tablets; chinese medicines; and proxymetacaine hydrochloride, bendazac lysine, timolol maleate, gatifloxacin, jinzhen, pemirolast potassium, and compound dextran eye drops. Further, it provides paeonol ointment, kecuo yintong gel, compound tujingpi gel, metformin and glipizide tablets, and itraconazole and armillarisin oral solution. The company was incorporated in 2002 and is based in Hefei, China.
Hefei Lifeon Pharmaceutical Co Ltd management
6- Mr. Huanxi CuiGM & Director · born 1979
- Ms. Yi LiuCFO & Head of Accounting · born 1988
- Mr. Tianhe DaiDeputy General Manager · born 1977
- Mr. Tiecheng JiDeputy GM & Director · born 1992
- Mr. Jun XiaDeputy GM & Secretary of the Board · born 1983
- Mr. Yong ZhengDeputy General Manager · born 1972